Date of approval.................................

FREEDOM OF INFORMATION SUMMARY

Micotil® 300 Injection
(tilmicosin phosphate)

Supplement to NADA 140-929

“...for the treatment of ovine respiratory disease (ORD) associated with *Mannheimia (Pasteurella) haemolytica*.”

SUBMITTED BY:
ELANCO ANIMAL HEALTH
# TABLE OF CONTENTS

1. GENERAL INFORMATION ................................................................. Page 3
2. EFFECTIVENESS ........................................................................ Page 4
3. ANIMAL SAFETY .......................................................................... Page 5
4. HUMAN SAFETY ........................................................................ Page 6
   a. Toxicology .................................................................................. Page 6
   b. Safe Concentration of Total Residues ........................................... Page 6
   c. Total Residue and Metabolism Studies ...................................... Page 6
   d. Tolerance for Marker Residue ..................................................... Page 9
   e. Withdrawal Period ..................................................................... Page 10
   f. Analytical Methods for Residues ................................................. Page 12
   g. User Safety Concerns ................................................................. Page 12
5. AGENCY CONCLUSIONS ............................................................... Page 13
6. ATTACHMENTS ........................................................................... Page 14
I. GENERAL INFORMATION:

a. NADA Number: 140-929

b. Sponsor: Elanco Animal Health
A Division of Eli Lilly & Co.,
Lilly Corporate Center,
Indianapolis, IN 46285

Drug Labeler Code: 000986

c. Established Name: Tilmicosin phosphate

d. Proprietary Name: Micotil® 300 Injection

e. Dosage Form: Ready-to-use injectable solution

f. How Supplied: 50 mL, 100 mL, and 250 mL multidose amber glass bottles

g. How Dispensed: Rx

h. Amount of Active Ingredient: 300 mg tilmicosin as tilmicosin phosphate per mL

i. Route of Administration: subcutaneous injection

j. Species/Class: Ovine/sheep

k. Recommended Dosage: a single subcutaneous injection of 10 mg/kg body weight (1 mL/30 kg or 1.5 mL/100 lb body weight)

l. Pharmacological Category: antimicrobial

m. Indications: Micotil® 300 Injection is indicated for the treatment of ovine respiratory disease (ORD) associated with Mannheimia (Pasteurella) haemolytica.

n. Effect of Supplement: Provides for the use of tilmicosin phosphate (Micotil® 300) in a new animal species, sheep.
2. **EFFECTIVENESS:**

Section 514.1(d) of Title 21 of the Code of Federal Regulations (CFR) permits extrapolation of data from a major species to a minor species to satisfy the requirements of section 512 of the Federal Food, Drug, and Cosmetic Act with respect to the effectiveness of a new animal drug. A combination of data from sheep (a minor species) and a closely-related approved major species (cattle) were used to support the determination of effectiveness, consistent with the Guideline for Industry – FDA Approval of New Animal Drugs for Minor Uses and minor Species (Guideline #61 FDA/CVM April 1999).

For the purposes of this supplement for use in sheep, a determination of medical equivalence was based on a pharmacokinetic comparison demonstrating that serum concentrations of tilmicosin in sheep and cattle are comparable when tilmicosin is administered as a single subcutaneous injection at a rate of 10 mg/kg. The data for the effectiveness study was generated under INAD 9693 and submitted in a Public Master File (PMF) 5673. A notice of availability of this PMF is published in the Federal Register (65 FR 47992, August 4, 2000).
3. **TARGET ANIMAL SAFETY:**

The comparative study of tilmicosin pharmacokinetics, conducted under INAD 9693 and published under PMF 5673, in sheep and cattle indicates that the target animal safety of tilmicosin should be comparable in sheep and cattle when administered as a single subcutaneous injection at 10 mg/kg. None of the animals died during the study and no adverse effects of tilmicosin were observed on blood pressure, heart rate, or respiration rate of sheep. The results indicate that tilmicosin can be used safely in sheep at the recommended dose for sheep with a minimum body weight of 15 kg. The availability of this data in PMF 5673 is published in the Federal Register (65 FR 47992, August 4, 2000).
4. **HUMAN SAFETY:**

a. Toxicology

See the Freedom of Information (FOI) Summary for the approval of the original application for MICOTIL® 300 (NADA 140-929), approved March 24, 1992. A copy of this FOI summary can be obtained from Mrs. Marylin H. Broderick, HFV-12, Center for Veterinary Medicine, 7500 Standish Place, Rockville, MD 20855.

b. **Safe Concentration of Total Residues:**

1) Acceptable Daily Intake (ADI): The ADI previously established for tilmicosin is 1.5 mg/person/day or (25 μg/kg body weight/day for a 60 kg person).

Ref. 21 CFR 556.735.

2) Safe Tissue Concentrations (STC):

The STC is calculated by dividing the ADI per person by the tissue consumption factors (300 g/day for muscle, 50 g/day for kidney or fat, and 100 g/day for liver.

\[
\text{STC}_{\text{muscle}} = \frac{1.5 \text{ mg/day}}{300 \text{ g/day}} = 5 \mu g/g = 5 \text{ ppm}
\]

\[
\text{STC}_{\text{kidney or fat}} = \frac{1.5 \text{ mg/day}}{50 \text{ g/day}} = 30 \mu g/g = 30 \text{ ppm}
\]

\[
\text{STC}_{\text{liver}} = \frac{1.5 \text{ mg/day}}{100 \text{ g/day}} = 15 \mu g/g = 15 \text{ ppm}
\]

c. **Total Residue and Metabolism Studies**

Total residues of $^{14}$C-tilmicosin in sheep tissues were evaluated in two studies.

1) **Study HRC/LLY36/930447**


Huntingdon Research Centre Ltd., Huntingdon, Cambridgeshire, U.K.

The purpose of this study was to evaluate the excretion profile of $^{14}$C tilmicosin; to assess the depletion of total radioactive residues in edible tissues; to establish the metabolic profiles in edible tissues and compare them with the metabolic profile in urine and to identify and quantify the major metabolites of tilmicosin in sheep.
Fourteen, 10 to 11 week old Beulah-cross lambs, 16 to 23 kg body weight were administered a single subcutaneous injection of $^{14}$C tilmicosin at 20 mg/kg body weight. Plasma samples were collected at 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144 and 168 hours after dosing. Urine and feces were collected at pre-dose and in 24-hour intervals for up to 7 days from time of dosing. Tissue samples of liver, kidney, lung, skeletal muscle, fat and injection site were collected for radioactivity assay and TLC and HPLC analyses.

A mean total of 85.2% of the radioactivity dosed was excreted in the 7 days after dosing. The majority of the radioactivity was excreted in the feces (a mean of 71.9%). The urine contained a mean of 13.2% of the total dose in the 7 days. Mean concentrations of radioactivity in tissues of treated sheep are summarized in Table 4.1.

Parent tilmicosin accounted for approximately 75% of the urinary radioactivity with metabolites T-1 and T-2 accounting for <1% of the dose. In the liver and kidney, parent tilmicosin and metabolite T-2 were the major components. The concentration of parent tilmicosin in the liver declined while T-2 correspondingly increased as withdrawal time increased.

Table 4.1: Concentrations (ppm) (Mean ± SD) of radioactivity in tissues of sheep following a single subcutaneous dose of $^{14}$C-tilmicosin at a dose of 20 mg/kg body weight

<table>
<thead>
<tr>
<th>Tissue</th>
<th>Sacrifice (days)</th>
<th>3</th>
<th>7</th>
<th>21</th>
<th>28</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liver</td>
<td>9.98±0.78</td>
<td>5.77±0.30</td>
<td>3.67±0.72</td>
<td>2.70±0.60</td>
<td></td>
</tr>
<tr>
<td>Kidneys</td>
<td>21.09±4.49</td>
<td>4.07±1.35</td>
<td>1.42±0.89</td>
<td>0.55±0.13</td>
<td></td>
</tr>
<tr>
<td>Omental Fat</td>
<td>&lt;1.36</td>
<td>&lt;1.32</td>
<td>&lt;1.32</td>
<td>&lt;1.35</td>
<td></td>
</tr>
<tr>
<td>Renal Fat</td>
<td>&lt;1.24</td>
<td>&lt;1.15</td>
<td>&lt;1.17</td>
<td>&lt;1.20</td>
<td></td>
</tr>
<tr>
<td>Muscle</td>
<td>1.26±0.18</td>
<td>0.57</td>
<td>&lt;0.26</td>
<td>&lt;0.26</td>
<td></td>
</tr>
<tr>
<td>Lungs</td>
<td>5.11±0.08</td>
<td>1.53±0.07</td>
<td>NS*</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>Inj. Site Skin</td>
<td>63.02±25.80</td>
<td>18.74±5.50</td>
<td>32.91±28.83</td>
<td>6.51±5.69</td>
<td></td>
</tr>
<tr>
<td>Inj. Site Muscle</td>
<td>43.19±0.33</td>
<td>14.38±2.11</td>
<td>5.32±6.00</td>
<td>1.32±0.51</td>
<td></td>
</tr>
</tbody>
</table>

*Not sampled
2) Study CVLS4/92


Central Veterinary Laboratory, Weybridge, Addlestone, KT15 3NB, U.K.

The depletion and quantification of 14C tilmicosin in plasma and tissues was studied in 16 sheep after subcutaneous administration of 20 mg/kg body weight tilmicosin. Plasma was collected at 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144 and 168 hours after dosing. Kidney, liver, fat, muscle, injection site and lung tissues were collected at days 3, 7, 21 and 28 post-injection. The plasma and tissue samples were assayed by validated HPLC methods.

Values for the mean plasma concentration of tilmicosin ranged from 958.8 ng/mL (T<sub>max</sub>) at 4 hours post-injection to below the validated limit of determination (50 ng/mL or 0.05 ppm) at 48 hours post-injection. Between 6 and 24 hours, T<sub>1/2</sub> was approximately 7 hours and between 48 and 96 hours, T<sub>1/2</sub> was approximately 41 hours.

Concentrations of tilmicosin were highest in the injection site and kidney at Day 3 post-injection. At Day 28, mean tilmicosin concentration was 160.0 ng/g (0.16 µg/g) in the liver, 122 ng/g (0.12 µg/g) in the injection site and 63 ng/g (0.63 µg/g) in the kidney. Tilmicosin was not detected in muscle and fat 21 and 28 days after dosing above the limit of detection of the method (50 ppb). Mean concentrations (ppb) of tilmicosin in the tissues of treated sheep are summarized in Table 4.2.

Table 4.2: Concentrations (mean ± SD) of tilmicosin in sheep tissues

<table>
<thead>
<tr>
<th>Tissue</th>
<th>3</th>
<th>7</th>
<th>21</th>
<th>28</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liver</td>
<td>2444.0±278.6*</td>
<td>733.0±43.8</td>
<td>310.0±162.7</td>
<td>160.0±116.2</td>
</tr>
<tr>
<td>Kidney</td>
<td>12414.0±5226.5</td>
<td>1286.0±500.6</td>
<td>467.3±352.9</td>
<td>73.0±29.9</td>
</tr>
<tr>
<td>Muscle</td>
<td>478.5±186.0</td>
<td>193.5±202.9</td>
<td>ND†</td>
<td>ND</td>
</tr>
<tr>
<td>Renal Fat</td>
<td>73.0±14.1</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Injection Site</td>
<td>20352±3369.7</td>
<td>7067.3±1019.1</td>
<td>3626.5±3544.6</td>
<td>121.8±28.4</td>
</tr>
<tr>
<td>Lung</td>
<td>2810.3±871.0</td>
<td>322.5±111.0</td>
<td>NS††</td>
<td>NS</td>
</tr>
</tbody>
</table>

*Values are reported as ppb
†Not determined
††Not sampled
Sheep injected subcutaneously with $^{14}$C tilmicosin at 20 mg/kg body weight excrete 85% of the dose within the first 7 days. Plasma concentrations of tilmicosin decline close to the limits of detection by 36 hours. Tissue concentrations of tilmicosin in all tissues are less than the safe concentration for total residues at all sampling times studied and well below the safe concentrations 28 days after dosing.

Because parent tilmicosin accounts for a substantial portion of the dose in urine and of the residue in kidney and liver, it is selected as the marker residue. As in cattle, liver is selected as the target tissue.

Although a separate comparative metabolism report was not provided, a review of work previously conducted to support NADA 140-929 along with the metabolism data provided for sheep demonstrate that the metabolic profiles for sheep and the toxicological species, the rat, are comparable. Therefore, the toxicological species has been autoexposed to the metabolites of tilmicosin present in the edible tissues of treated sheep.

d. Tolerance for the Marker Residue

The total residue and metabolism study in sheep demonstrates that the marker residue, parent tilmicosin, represents approximately 20% of the total residue in liver. When this percentage is applied to the calculated safe concentrations, a tolerance of 3 ppm is calculated for residues of tilmicosin in liver. Applying the 20% to the muscle safe concentration results in a calculated muscle tolerance of 1 ppm. However, consistent with the requested withdrawal period, we are assigning tolerances of 1.2 ppm for sheep liver and 0.1 ppm for sheep muscle. A liver tolerance of 1.2 ppm is the same tolerance value currently assigned to cattle. A muscle tolerance of 0.1 ppm for residues of parent tilmicosin in sheep muscle is the same as the muscle tolerance assigned to cattle and consistent with the Maximum Residue Limit recommended by the 47th meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA), Rome 1996. Additionally, the analytical method has an LOQ of half the proposed muscle tolerance and can serve as a monitoring method for residues of tilmicosin in sheep tissues. We propose to assign a withdrawal period of 28 days for the use of tilmicosin, as Micotil® 300, in sheep as a single subcutaneous injection at a dose of up to 10 mg/kg body weight.
e. Withdrawal Period

Depletion of residues in the edible tissue of sheep was evaluated in two studies:

1) Study CVLS6/91


Analytical Chemistry Unit, Central Veterinary Laboratory, New Haw, Weybridge, Surrey KT15 3NB.

The purpose of this study was to measure residues of tilmicosin in sheep after subcutaneous administration to establish an approximate withdrawal period for the parent drug.

Twenty-four 6 month old sheep, Scottish Blackface, 30 to 40 kg body weight were administered single subcutaneous doses of 30 mg tilmicosin/kg body weight into the left dorsolateral chest wall. Liver, kidney, muscle, fat and injection site tissues were collected at Days 14, 21, 28, 35, 42 and 56 post-injection and analyzed by a validated HPLC method with a limit of determination of 50 ng/g (50 ppb).

The highest mean concentration of tilmicosin was in liver at Day 14 (1554 ng/g) and the minimum concentration of tilmicosin was obtained in muscle and fat (all values were below the limit of determination). At Day 28, the mean concentration of tilmicosin in liver was 418.0 ng/g, at injection site, 150.3 ng/g, and in kidney, 82.0 ng/g. At Day 28, residues in muscle and fat residues fell below the limit of determination (50 ppb). Mean concentrations (ppb) of tilmicosin in sheep tissues are summarized in Table 4.3.

Table 4.3: Concentration (ppb) of tilmicosin residues in sheep tissues following subcutaneous administration of Micotil® 300 at a dose of 30 mg/kg body weight

<table>
<thead>
<tr>
<th>Tissue</th>
<th>14</th>
<th>21</th>
<th>28</th>
<th>35</th>
<th>42</th>
<th>56</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liver</td>
<td>1554±160</td>
<td>1170±213</td>
<td>418±208</td>
<td>310±126</td>
<td>199±106</td>
<td>81±19</td>
</tr>
<tr>
<td>Kidney</td>
<td>478±178</td>
<td>148±65</td>
<td>93±6</td>
<td>68±4</td>
<td>51</td>
<td>&lt;LOQ</td>
</tr>
<tr>
<td>Muscle</td>
<td>&lt;LOQ</td>
<td>&lt;LOQ</td>
<td>&lt;LOQ</td>
<td>&lt;LOQ</td>
<td>&lt;LOQ</td>
<td>&lt;LOQ</td>
</tr>
<tr>
<td>Fat</td>
<td>&lt;LOQ</td>
<td>&lt;LOQ</td>
<td>&lt;LOQ</td>
<td>&lt;LOQ</td>
<td>&lt;LOQ</td>
<td>&lt;LOQ</td>
</tr>
<tr>
<td>Injection Site</td>
<td>506±310</td>
<td>641±469</td>
<td>150±95</td>
<td>159±103</td>
<td>161±84</td>
<td>81±29</td>
</tr>
</tbody>
</table>

LOQ=50 ppb
Tilmicosin was metabolized and/or excreted to a great extent during the study interval. Because the dose was three fold higher than the proposed therapeutic dose, residues would be expected to be lower in animals treated with the proposed dose, 10 mg/kg.

2) Study CVLS/23/95


Analytical Chemistry Unit, Central Veterinary Laboratory, New Haw, Addlestone, Surrey KT15 3NB.

The purpose of this study was to determine the residues of tilmicosin in tissues at various withdrawal time points after its subcutaneous administration to sheep at the intended use level.

Twenty-eight Swaledale sheep in the weight range 26.2 to 51.2 kg body weight were divided into seven groups of four sheep per group, consisting of 2 males and 2 females. Six of the seven groups were administered single subcutaneous doses of 10 mg tilmicosin/kg body weight into the left dorsolateral chest wall. The seventh group was designated as control and received no injection. Each group was designated for slaughter at one of the following times post-treatment: 14, 21, 28, 35, 42, or 49 days. (The four sheep in the control group were designated for slaughter at 14 days.)

Liver, kidney, thigh muscle, renal fat and injection site tissues were collected at slaughter and analyzed by a validated HPLC method. Mean concentrations (ppb) of tilmicosin in sheep tissues are summarized in Table 4.4.

Table 4.4: Concentration (ppb) of tilmicosin residues in sheep tissues following subcutaneous administration of Micotil® 300 at a dose of 10 mg/kg body weight

<table>
<thead>
<tr>
<th>Tissue</th>
<th>14</th>
<th>21</th>
<th>28</th>
<th>35</th>
<th>42</th>
<th>49</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liver</td>
<td>107±11</td>
<td>80±43</td>
<td>&lt;LOQ</td>
<td>59</td>
<td>&lt;LOQ</td>
<td>&lt;LOQ</td>
</tr>
<tr>
<td>Kidney</td>
<td>162±76</td>
<td>73±16</td>
<td>&lt;LOQ</td>
<td>&lt;LOQ</td>
<td>&lt;LOQ</td>
<td>&lt;LOQ</td>
</tr>
<tr>
<td>Muscle</td>
<td>&lt;LOQ</td>
<td>&lt;LOQ</td>
<td>&lt;LOQ</td>
<td>&lt;LOQ</td>
<td>&lt;LOQ</td>
<td>&lt;LOQ</td>
</tr>
<tr>
<td>Fat</td>
<td>&lt;LOQ</td>
<td>&lt;LOQ</td>
<td>&lt;LOQ</td>
<td>&lt;LOQ</td>
<td>&lt;LOQ</td>
<td>&lt;LOQ</td>
</tr>
<tr>
<td>Injection Site</td>
<td>1527±504</td>
<td>143±55</td>
<td>80±30</td>
<td>&lt;LOQ</td>
<td>&lt;LOQ</td>
<td>&lt;LOQ</td>
</tr>
</tbody>
</table>

LOQ=50 ppb
The highest mean concentration of tilmicosin was in injection site tissue at Day 14 (1527 ng/g for the average of the four sheep) and the minimum concentration of tilmicosin was obtained in muscle and fat (all values were below the LOQ for the method).

The mean residue concentration in the liver tissue was 107 ng/g at Day 14. Residues in liver were less than the LOQ by Day 49.

Summary of the two residue studies is presented in Table 4.5.

Table 4.5. Summary of residues detected at Day 28 post-injection for the two studies

<table>
<thead>
<tr>
<th>Study no.</th>
<th>Dose</th>
<th>Liver</th>
<th>Kidney</th>
<th>Muscle</th>
<th>Fat</th>
<th>Injection Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>HRC/Y36/930447</td>
<td>$^{14}$C</td>
<td>2.70±0.60</td>
<td>0.55±0.13</td>
<td>&lt;0.26*</td>
<td>&lt;1.20*</td>
<td>1.32±0.51</td>
</tr>
<tr>
<td></td>
<td>20 mg/kg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CVLS4/92</td>
<td>$^{14}$C</td>
<td>0.16±0.12</td>
<td>0.07±0.03</td>
<td>ND†</td>
<td>ND</td>
<td>0.12±0.03</td>
</tr>
<tr>
<td></td>
<td>20 mg/kg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CVLS6/91</td>
<td>cold</td>
<td>0.42±0.21</td>
<td>0.09±0.01</td>
<td>ND</td>
<td>ND</td>
<td>0.16±0.1</td>
</tr>
<tr>
<td></td>
<td>30 mg/kg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CVLS/23/95</td>
<td>cold</td>
<td>&lt;LOQ</td>
<td>&lt;LOQ</td>
<td>ND</td>
<td>ND</td>
<td>0.08±0.03</td>
</tr>
<tr>
<td></td>
<td>10 mg/kg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Below limits of detection
†not detected
Limit of quantitation (LOQ) = 0.05 μg/g

These studies confirm that residues of tilmicosin resulting from a single subcutaneous injection of Micotil® 300 to sheep at a dose of 10 mg/kg body weight are below the assigned liver and muscle tolerance levels 28 days after treatment, the assigned withdrawal period.

f. Analytical Methods for Residues

The regulatory analytical method for residues is a reverse phase HPLC method with UV detection. The method is available from Residue Chemistry Team (HFV-151), Center for Veterinary Medicine, 7500 Standish Place, Rockville, MD 20855.

g. User Safety Concerns

User safety concerns associated with direct contact have been satisfactorily addressed by establishing label warnings. In addition, a toll-free number is provided on the label for additional information and reporting adverse events.
5. **AGENCY CONCLUSIONS:**

The data submitted in support of this supplemental NADA satisfy the requirements of Section 512 of the Food, Drug, and Cosmetic Act and 21 CFR 514.1 of the implementing regulations. The data demonstrate that Micotil® 300 Injection (tilmicosin phosphate), when used under labeled conditions of use is safe and effective for the treatment of ovine respiratory disease (ORD) associated with *Mannheimia (Pasteurella) haemolytica*.

The human food safety data demonstrate that residues resulting from a single subcutaneous injection of tilmicosin to sheep at a dose of 10 mg/kg body weight are below the assigned liver and muscle tolerance levels 28 days after treatment, the assigned withdrawal period.

The product remains a prescription drug for safe and effective use by a veterinarian for the treatment of properly diagnosed pneumonia in sheep.

This approval does not qualify for marketing exclusivity under Section 512(c)(2)(F)(iii) of the Federal Food, Drug, and Cosmetic Act.

In accordance with 21 CFR 514.106(b)(2)(vii), this is a Category II change. This supplement provides for the use of tilmicosin in sheep, a new animal species. The approval of this change is not expected to have any adverse effect on the safety or effectiveness of this new animal drug. Accordingly, this approval did not require a reevaluation of the safety and effectiveness data in the parent application.

Tilmicosin is under U.S. patent number 4,820,695 expiring April 11, 2006.
6. ATTACHMENTS:
   
   A. Facsimile Rx labeling for 50 mL, 100 mL, and 250 mL bottles.
   B. Facsimile package insert
CAUTION: Do Not Administer to Swine. Injection in Swine Has Been Shown to be Fatal.

WARNING: Animals intended for human consumption must not be slaughtered within 28 days of the last treatment. Do not use in female dairy cattle 20 months of age or older. Use of tilmicosin in this class of cattle may cause milk residues. Do not use in lactating ewes if the milk is intended for human consumption.

CAUTION: The safety of tilmicosin has not been established in pregnant cattle and in animals used for breeding purposes. Intramuscular injection will cause a local reaction which may result in trim loss. The safety of tilmicosin

Micotel® 300 Injection

Tilmicosin injection, USP

CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

NOTE TO THE PHYSICIAN: The cardiovascular system appears to be the target of toxicity. This antibiotic persists in tissues for several days. The cardiovascular system should be monitored closely and supportive treatment provided. Dobutamine partially offset the negative inotropic effects induced by Micotil in dogs. ß-adrenergic antagonists, such as propranolol, exacerbated the negative inotropy of Micotil-induced tachycardia in dogs. Epinephrine potentiated lethality of Micotil in pigs.

For cattle, injection under the skin behind the shoulders and over the rib suggested. For sheep, injection in a skin fold behind the shoulders and over the rib suggested. Note—Swelling at the subcutaneous site of injection may be observed but is usually mild.

CONTRAINDICATION: Do not use in automatically powered syringes. Do not administer intravenously to cattle or sheep. Intravenous injection in cattle or sheep will be fatal. Do not administer to animals other than cattle or sheep. Injection of this antibiotic has been shown to be fatal in swine and non-human primates, and it may be fatal in horses and goats.
Mannheimia (Pasteurella) haemolytica for at least 3 days following the single injection. Serum tilmicosin levels are a poor indicator of total body tilmicosin. The lung-serum tilmicosin ratio in favor of lung tissue appeared to equilibrate by 3 days post injection at approximately 60. In a study with radioactive tilmicosin, 24% and 66% of the dose was recovered from urine and feces, respectively, over 21 days.

Directions—Inject Subcutaneously in Cattle and Sheep Only. Administer a single subcutaneous dose of 10 mg/kg of body weight (1 mL/30 kg or 1.5 mL per 100 lbs). Do not inject more than 15 mL per injection site. Do not use in lambs less than 15 kg body weight. If no improvement is noted within 48 hours, the diagnosis should be reevaluated.

NOTA AL MÉDICO: EL SISTEMA CARDIOVASCULAR PARECERÍA EL BLANCO DE LA TOXICIDAD DE ESTE PRODUCTO. ESTE ANTIBIÓTICO PERSISTE EN LOS TEJIDOS POR VARIOS DÍAS. EL SISTEMA CARDIOVASCULAR DEBERÁ OBSERVARSE CUIDADOSAMENTE Y TRATAMIENTO DE SOPORTE DEBERÁ PROPORCIONARSE. DOBUTAMINA PARCIALMENTE BLOQUEA LOS EFECTOS INOTROPICOS NEGATIVOS INDUCIDOS POR MICOTIL EN PERROS. B-ADRENERGICOS ANTAGONISTAS, COMO EL PROPRANOLOL, EXERECEN LA INOTROPIA NEGATIVA DE LA TAQUICARDIA INDUCIDA POR MICOTIL EN PERROS. LA EPINEFRINA POTENCIALIZA LA LETALIDAD DE MICOTIL EN CERDOS.

minimal myocardial necrosis in some animals in the 50 mg/kg gr. Subcutaneous doses of 150 mg/kg injected at 72-hour intervals resulted in de: Edema was marked at the site of injection. Minimal myocardial necrosis was only lesion observed at necropsy. Deaths of cattle have been observed w: single intravenous dose of 5 mg/kg of body weight. In sheep, single subcutaneous injections of 10 mg/kg dose did not cause deaths and no adverse effects of tilmicosin were observed on blood press heart rate, or respiratory rate.

Pharmacology: A single subcutaneous injection of MICOTIL at 10 mg/kg of body weight dose in cattle resulted in peak tilmicosin levels within one hour detectable levels (0.07 μg/mL) in serum beyond 3 days. However, lung concen: tions of tilmicosin remained above the tilmicosin MIC 95% of 3.12 μg/mL
In monkeys, a single intramuscular dose of 10 mg/kg caused no signs of toxicity. A single dose of 20 mg/kg caused vomiting and 30 mg/kg caused the death of the only monkey tested.

In swine, intramuscular injection of 10 mg/kg caused increased respiration, emesis, and a convulsion. 20 mg/kg resulted in mortality in 3 of 4 pigs, and 30 mg/kg caused the death of all 4 pigs tested.

Results of genetic toxicology studies were all negative. Results of teratology and reproduction studies in rats were negative. The no-effect level in dogs after daily oral doses for up to one year is 4 mg/kg of body weight.

In cattle, subcutaneous doses of 10, 30, and 50 mg/kg of body weight, each injected 3 times at 72 hour intervals did not cause any death. An expected, edema at the site of injection was noted. The only lesion observed at necropsy was

**For Subcutaneous Use in Cattle and Sheep Only.**

**Do Not Use In Automatically Powered Syringes.**

**Indications:** Micotil® 300 is indicated for the treatment of bovine respiratory disease (BRD) and ovine respiratory disease (ORD) associated with *Mannheimia (Pasteurella) haemolytica*. Micotil® 300 is indicated for control of respiratory disease in cattle at high risk of developing it associated with *Mannheimia (Pasteurella) haemolytica*.

**Description:** Micotil® 300 is a solution of the antibiotic tilmicosin. Each contains 300 mg of tilmicosin, USP as tilmicosin phosphate in propylene glycol, phosphoric acid as needed to adjust pH and water injection, q.s.
Tilmicosin, USP is produced semi-synthetically and is in the macrolide class of antibotics.

**Actions:** Activity—Tilmicosin has an in-vitro antibacterial spectrum that is predominantly gram-positive with activity against certain gram-negative microorganisms. Activity against several mycoplasma species has also been detected.

Ninety-five percent of the *Mannheimia (Pasteurella) haemolytica* isolates were inhibited by 3.12 µg/mL or less.

<table>
<thead>
<tr>
<th>Microorganism</th>
<th>MIC (µg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Mannheimia (Pasteurella) haemolytica</em></td>
<td>3.12</td>
</tr>
<tr>
<td><em>Pasteurella multocida</em></td>
<td>6.25</td>
</tr>
<tr>
<td><em>Haemophilus somnus</em></td>
<td>6.25</td>
</tr>
</tbody>
</table>

*Mycoplasm dispar* 0.097  
*M. bovis* 0.024  
*M. bovis 0.048*

*The clinical significance of this in vitro data in cattle has not been demonstrated.

**Toxicology:** The heart is the target of toxicity in laboratory and domestic ani given Micocid 300 by oral or parenteral routes. The primary cardiac effects are increased heart rate (tachycardia) and decreased contractility (negrology).

Upon injection subcutaneously, the acute median lethal dose of tilmicosin is 97 mg per kg, and in rats is 185 mg/kg of body weight. Given orally, the median lethal dose is 800 mg/kg and 2250 mg/kg in fasted and nonfasted, respectively. No compound-related lesions were found at necropsy.
has not been established for sheep with a body weight of less than 15 k in pregnant sheep or sheep used for breeding purposes.

How Supplied: Micotil is supplied in 50 mL, 100 mL and 250 mL multidose amber glass bottles.

Storage: Store at room temperature, 86°F (30°C) or below. Protect from direct sunlight. Conserve a 86°F (30°C). Proteger de la directa luz solar.

*Eliaco®, Micotil®, and the diagonal color bar are trademarks of Eli Lilly and Company.

Text revised April 1, 2002

Manufactured for:
Eliaco Animal Health, A Division of Eli Lilly and Company
Indianapolis, IN 46285, USA

Manufactured by:
Eliaco Animal Health
A Division of Eli Lilly and Company
Indianapolis, IN 46285, USA
<table>
<thead>
<tr>
<th><strong>BLANCO</strong></th>
<th>Micell / Label / America</th>
<th>Product code: AH 0230</th>
<th>Artwork Ref. No: YL0071DEAMX_P2</th>
<th>Affiliate Proof No.: 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Created at/by: Speke/MIKE</td>
<td>Date Created: 24.04.2002</td>
<td>Last amended: 31.07.2002 Speke/MIKE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Label size: 50 mL</td>
<td>Artwork size: 90 mm W x 40 mm H</td>
<td>Studio approval:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Barcode: 419 (B) (L0L00L00)</td>
<td>File Type: QuarkXPress 4.0</td>
<td>(L,OK matches approved proof / file / ISDN)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary Pack: GPG080</td>
<td>Reason for Revision: PROOFS FOR FDA REGISTRATION.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Approved by:</td>
<td>Date:</td>
<td>Q.C. approved by:</td>
<td>Date:</td>
<td></td>
</tr>
</tbody>
</table>

Process colour reproduction may not match PANTONE-identified solid colour standards. Refer to current PANTONE Colour Publications for the accurate colour.
<table>
<thead>
<tr>
<th>Created at/by: Speke / MIKE</th>
<th>Date created: 22.04.2002</th>
<th>Last amendment: 26.04.2002 Speke / MIKE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pack size: 100 ml</td>
<td>Artwork size: 157 mm x 54 mm</td>
<td>Studio approval:</td>
</tr>
<tr>
<td>Pharma Code: 301 (B) (L000LO00)</td>
<td>File Type: Adobe Illustrator 8.01</td>
<td>Date:</td>
</tr>
<tr>
<td>Base Spec.: GPG021</td>
<td>Reason for Revision: REVISED PROOFS FOR FDA (No text approval code).</td>
<td></td>
</tr>
<tr>
<td>Approved by:</td>
<td>Q.C. approved by:</td>
<td>Date:</td>
</tr>
</tbody>
</table>

Process colour reproduction may not match PANTONE-identified solid colour standards. Refer to current PANTONE Colour Publications for the accurate colour.

100% PRINTOUT
Micotil® 300
Tilmicosin Injections, USP

CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.


Emergency medical telephone numbers are 1-800-722-0987 or 1-317-276-2000. Avoid contact with eyes.

NOTE TO PHYSICIAN: The cardiovascular system appears to be the target of toxicity. This antibiotic persists in tissues for several days. The cardiovascular system should be monitored closely and supportive treatment provided. Dobutamine partially offset the negative inotropic effects induced by Micotil in dogs. B-adrenergic antagonists, such as propranolol, exacerbated the negative inotropy of Micotil-induced tachycardia in dogs. Epinephrine potentiated lethality of micotil in pigs.


NOTA AL MEDICO: EL SISTEMA CARDIOVASCULAR PARECE SER EL BLANCO DE LA TOXICIDAD DE ESTE PRODUCTO. ESTE ANTIBIOTICO PERDURA EN LOS TEJIDOS POR VARIOS DIAS. EL SISTEMA CARDIOVASCULAR DEBERA OBSERVARSE CUIDADOSAMENTE Y TRATAMIENTO DE SOPORTE DEBERA PROPORCIONARSE. DOBUTAMINA PARCIALMENTE BLOQUEA LOS EFECTOS INOTROPICOS NEGATIVOS INDUCIDOS POR MICOTIL EN PERROS. BETA ADRENERGICOS ANTAGONISTAS, COMO EL PROPRANOLOL, EXACERBARON LA INOTROPIA NEGATIVA DE LA TAQUICARDIA INDUCIDA POR MICOTIL EN PERROS. LA EPINEFRINA POTENCIALIZA LA LETALIDAD DE MICOTIL EN CERDOS.

For Subcutaneous Use in Cattle and Sheep Only. Do Not Use in Automatically Powered Syringes.

Indications: Micotil 300 is indicated for the treatment of bovine respiratory disease (BRD) and ovine respiratory disease (ORD) associated with Mannheimia (Pasteurella) haemolytica. Micotil 300 is indicated for the control of respiratory disease in cattle at high risk of developing BRD associated with Mannheimia (Pasteurella) haemolytica.

Description: Micotil 300 is a solution of the antibiotic tilmicosin. Each mL contains 300 mg of tilmicosin, USP as tilmicosin phosphate in 25% propylene glycol, phosphoric acid as needed to adjust pH and water for injection, q.s.

Tilmicosin, USP is produced semi-synthetically and is in the macrolide class of antibiotics.

Actions: Activity—Tilmicosin has an in-vitro antibacterial spectrum that is predominantly gram-positive with activity against certain gram-negative microorganisms. Activity against several mycoplasmas species has also been detected. Ninety-five percent of the Mannheimia (Pasteurella) haemolytica isolates were inhibited by 3.12 μg/mL or less.

Microorganism Microorganism

<table>
<thead>
<tr>
<th>Microorganism</th>
<th>MIC* (μg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mannheimia (Pasteurella) haemolytica</td>
<td>3.12</td>
</tr>
<tr>
<td>Pasteurella multocida</td>
<td>6.25</td>
</tr>
<tr>
<td>Haemophilus somnus</td>
<td>6.25</td>
</tr>
<tr>
<td>Mycoplasma dispar</td>
<td>0.047</td>
</tr>
<tr>
<td>M. bovis (M. bovis)</td>
<td>0.024</td>
</tr>
<tr>
<td>M. bovoculi</td>
<td>0.048</td>
</tr>
</tbody>
</table>

*The clinical significance of this in vitro data in cattle has not been demonstrated.

Toxicology: The heart is the target of toxicity in laboratory and domestic animals given Micotil 300 by oral or parenteral routes. The primary cardiac effects are increased heart rate (tachycardia) and decreased contractility (negative inotropy).

Upon injection subcutaneously, the acute median lethal dose of tilmicosin in mice is 97 mg/kg and in rats is 195 mg/kg of body weight. Given orally, the median lethal dose is 800 mg/kg and
2250 mg/kg in fasted and nonfasted rats, respectively. No compound-related lesions were found at necropsy. In monkeys, a single intramuscular dose of 10 mg/kg caused no signs of toxicity. A single dose of 20 mg/kg caused vomiting and 30 mg/kg caused the death of the only monkey tested. In swine, intramuscular injection of 10 mg/kg caused increased respiration, emesis, and a convulsion; 20 mg/kg resulted in mortality in 3 of 4 pigs; and 30 mg/kg caused the death of all 4 pigs tested. Results of genetic toxicology studies were all negative. Results of teratology and reproduction studies in rats were negative. The no effect level in dogs after daily oral doses for up to one year is 4 mg/kg of body weight. In cattle, subcutaneous doses of 10, 30, and 50 mg/kg of body weight, each injected 3 times at 72-hour intervals did not cause any deaths. As expected, edema at the site of injection was noted. The only lesion observed at necropsy was minimal myocardial necrosis in some animals in the 50 mg/kg group. Subcutaneous doses of 150 mg/kg injected at 72-hour intervals resulted in deaths. Edema was marked at the site of injection. Minimal myocardial necrosis was the only lesion observed at necropsy. Deaths of cattle have been observed with a single intravenous dose of 5 mg/kg of body weight. In sheep, single subcutaneous injections of 10 mg/kg dose did not cause any deaths and no adverse effects of tilmicosin were observed on blood pressure, heart rate, or respiratory rate.

Pharmacology: A single subcutaneous injection of tilmicosin at 10 mg/kg of body weight dose in cattle resulted in peak tilmicosin levels within one hour and detectable levels (0.07 μg/mL) in serum beyond 3 days. However, lung concentrations of tilmicosin remained above the tilmicosin MIC 95% of 3.13 μg/mL for Mannheimia (Pasteurella) haemolytica for at least 3 days following the single injection. Serum tilmicosin levels are a poor indicator of total body tilmicosin. The lung/serum tilmicosin ratio in favor of lung tissue appeared to equilibrate by 3 days post injection at approximately 60. In a study with radioactive tilmicosin, 24% and 58% of the dose were recovered from urine and feces, respectively, over 21 days.

Directions—Inject Subcutaneously in Cattle and Sheep Only. Administer a single subcutaneous dose of 10 mg/kg of body weight (1 mL/50 kg or 1.5 mL/100 lbs). Do not inject more than 15 mL per injection site. Do not use in lambs less than 15 kg body weight. If no improvement is noted within 48 hours, the diagnosis should be reevaluated.

For cattle, injection under the skin behind the shoulders and over the ribs is suggested. For sheep, injection in a skin fold behind the shoulders and over the ribs is suggested.

Note—Swelling at the subcutaneous site of injection may be observed but is transient and usually mild.

CONTRAINDICATION: Do not use in automatically powered syringes. Do not administer intravenously to cattle or sheep. Intravenous injection in cattle or sheep will be fatal. Do not administer to animals other than cattle or sheep. Injection of this antibiotic has been shown to be fatal in swine and non-human primates, and it may be fatal in horses and goats.

CAUTION: Do Not Administer to Swine. Injection In Swine Has Been Shown to be Fatal.

WARNINGS: Animals intended for human consumption must not be slaughtered within 28 days of the last treatment. Do not use in female dairy cattle 20 months of age or older. Use of tilmicosin in this class of cattle may cause milk residues. Do not use in lactating ewes if the milk is intended for human consumption.
Do Not Use in Automatically Powered Syringes.
No Administrar con Jeringas Accionadas Automáticamente.

**CAUTION:** Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.
An antibiotic injection for subcutaneous use in cattle and sheep. For the treatment of bovine respiratory disease (BRD) or ovine respiratory disease (ORD) associated with Mannheimia (Pasteurella) haemolytica. For the control of respiratory disease in cattle at high risk of developing BRD associated with Mannheimia (Pasteurella) haemolytica.

**HUMAN WARNING:** Not for human use. Injection of this drug in humans may be fatal. Keep out of reach of children. Do not use in automatically powered syringes. If accidentally given to humans, immediately seek medical attention. In case of human injection, consult a physician immediately. Emergency medical telephone numbers are 1-800-722-0077 or 1-317-771-2000. Avoid contact with eyes.

**WARNING:** Animals treated for human consumption must not be slaughtered within 30 days of the last treatment. Do not use in homicide cattle 30 months of age or older. Do not use in beef cattle to be slaughtered for meat. Do not use in sheep. If the label is intended for human consumption, consult a physician immediately.

**CAUTION:** The safety of this product has not been established in pregnant or nursing animals or in unweaned young. Do not use in a lactating cow, calf, or young. Do not use in pregnant or nursing animals. If the product is intended for human consumption, consult a physician immediately.


Manufactured by: Elanco Animal Health
A Division of Eli Lilly & Company
Indianapolis, IN 46282, USA

ELANCO® Micotil® RDO
250 ml

NOTE TO PHYSICIAN: The cardiovascular system appears to be the target of toxicity. This antibiotic persists in tissues for several days. The cardiovascular system should be monitored closely and supportive treatment provided. Dobutamine partially offset the negative inotropic effects induced by Micotil® in dogs. β-adrenergic antagonists, such as propranolol, exacerbated the negative inotropy of Micotil-induced tachycardia in dogs. Epinephrine potentiated lethality of Micotil® in pigs.

NOTA AL MEDICO: EL SISTEMA CARDIOVASCULAR PARECE SER EL BLANCO DE LA TOXICIDAD DE ESTE PRODUCTO. ESTE ANTIBIÓTICO PERSISTE EN LOS TEJIDOS POR VARIOS DIAS. EL SISTEMA CARDIOVASCULAR DEBERÁ OBSERVARSE CUIDADOSAMENTE Y TRATAMIENTO DE SOPORTE DEBERÁ PROPORCIONARSE. DOBUTAMINA PARCIALMENTE BLOQUEA LOS EFECTOS INOTROPICOS NEGATIVOS INDUCIDOS POR MICOTIL EN PERROS. BETA ADRENÉRGICOS ANTAGONISTAS, COMO EL PROPRANOLOL, EXACERBARON LA INOTROPIA NEGATIVA DE LA TAQUICARDIA INDUCIDA POR MICOTIL EN PERROS. LA EPINEFRINA POTENCIALIZA LA LETALIDAD DE MICOTIL EN CERDOS.

¿Esto es compartido para un producto veterinario o de uso humano? Este es un producto veterinario.

Storage: Store at room temperature, 66°F (30°C) or below. Protect from direct sunlight.

Conservar a 66°F (30°C). Proteger de la directa luz solar.

*Elanco® and Micotil® are trademarks of Eli Lilly and Company

Text Revised April ( ), 2002

Manufactured for:
Elanco Animal Health
A Division of Eli Lilly and Company
Indianapolis, IN 46285, USA

YL0061DEAMX
Description: Micotil 300 is a solution of the antibiotic tilmicosin. Each mL contains 300 mg of tilmicosin, USP as tilmicosin phosphate in 25% propylene glycol, phosphoric acid as needed to adjust pH and water for injection, q.s. Tilmicosin, USP is produced semi-synthetically and is in the macrocide class of antibiotics.

Actions: Activity—Tilmicosin has an in-vitro antibacterial spectrum that is predominantly gram-positive with activity against certain gram-negative microorganisms. Activity against several mycoplasma species has also been reported.

Fifty-five percent of the Mannheimia (Pasteurella) haemolytica isolates were inhibited by 3.12 μg/mL or less.

<table>
<thead>
<tr>
<th>Microorganism</th>
<th>MIC* (μg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mannheimia (Pasteurella) haemolytica</td>
<td>3.12</td>
</tr>
<tr>
<td>Pasteurella multocida</td>
<td>6.25</td>
</tr>
<tr>
<td>Haemophilus somnus</td>
<td>6.25</td>
</tr>
<tr>
<td>Mycoplasma dispar</td>
<td>0.097</td>
</tr>
<tr>
<td>M. ovitihinis</td>
<td>0.024</td>
</tr>
<tr>
<td>M. bovis</td>
<td>0.048</td>
</tr>
</tbody>
</table>

*The clinical significance of this in vitro data in cattle has not been demonstrated.
Toxicology: The heart is the target of toxicity in laboratory and domestic animals given Micotil® 300 by oral or parenteral routes. The primary cardiac effects are increased heart rate (tachycardia) and decreased contractility (negative inotropy).

Upon injection subcutaneously, the acute median lethal dose of tilmicosin in mice is 97 mg per kg, and in rats is 185 mg/kg of body weight. Given orally, the median lethal dose is 800 mg/kg and 2250 mg/kg in fasted and nonfasted rats, respectively. No compound-related lesions were found at necropsy.

In monkeys, a single intramuscular dose of 10 mg/kg caused no signs of toxicity. A single dose of 20 mg/kg caused vomiting and 30 mg/kg caused the death of the only monkey tested.

In swine, intramuscular injection of 10 mg/kg caused increased respiration, emesis, and a convulsion, 20 mg/kg resulted in mortality in 3 of 4 pigs, and 30 mg/kg caused the death of all 4 pigs tested.

Results of genetic toxicology studies were all negative. Results of teratology and reproduction studies in rats were negative. The no effect level in dogs after daily oral doses for up to one year is 4 mg/kg of body weight.

In cattle, subcutaneous doses of 10, 30, and 50 mg/kg of body weight, each injected 3 times at 72-hour intervals did not cause any deaths. As expected, edema at the site of injection was noted. The only lesion observed at necropsy was minimal myocardial necrosis in some animals in the 50 mg/kg group. Subcutaneous doses of 150 mg/kg injected at 72-hour intervals resulted in deaths. Edema was marked at the site of injection. Minimal myocardial necrosis was the only lesion observed at necropsy. Deaths of cattle have been observed with a single
Intravenous dose of 5 mg/kg of body weight.

In sheep, single subcutaneous injections of 10 mg/kg dose did not cause any deaths and no adverse effects of tilmicosin were observed on blood pressure, heart rate, or respiratory rate.

Pharmacology: A single subcutaneous injection of Micosil at 10 mg/kg of body weight dose in cattle resulted in peak tilmicosin levels within one hour and detectable levels (0.07 µg/mL) in serum beyond 3 days. However, lung concentrations of tilmicosin remained above the tilmicosin MIC 95% of 3.12 µg/mL for Mannheimia (Pasteurella) haemolytica for at least 3 days following the single injection. Serum tilmicosin levels are a poor indicator of total body tilmicosin. The lung-serum tilmicosin ratio in favor of lung tissue appeared to equilibrate by 3 days post injection at approximately 60. In a study with radioactive tilmicosin, 24% and 66% of the dose was recovered from urine and feces respectively over 21 days.

Directions—Inject Subcutaneously in Cattle and Sheep Only. Administer a single subcutaneous dose of 10 mg/kg of body weight (1 mL/30 kg or 1.5 mL per 100 lbs).

Do not inject more than 15 mL per injection site.

Do not use in lambs less than 15 kg body weight.

If no improvement is noted within 48 hours, the diagnosis should be reevaluated.

For cattle, injection under the skin behind the shoulders and over the ribs is suggested.

For sheep, injection in a skin fold behind the shoulders and over the ribs is suggested.
CONTRAINDICATION: Do not use in automatically powered syringes. Do not administer intravenously to cattle or sheep. Intravenous injection in cattle or sheep will be fatal. Do not administer to animals other than cattle or sheep. Injection of this antibiotic has been shown to be fatal in swine and non-human primates, and it may be fatal in horses and goats.

CAUTION: Do Not Administer to Swine. Injection in Swine Has Been Shown to be Fatal.

WARNINGS: Animals intended for human consumption must not be slaughtered within 28 days of the last treatment. Do not use in female dairy cattle 20 months of age or older. Use of tilmicosin in this class of cattle may cause milk residues. Do not use in lactating ewes if the milk is intended for human consumption.

CAUTION: The safety of tilmicosin has not been established in pregnant cattle and in animals used for breeding purposes. Intramuscular injection will cause a local reaction which may result in trim loss. The safety of tilmicosin has not been established for sheep with a body weight of less than 15 kg or in pregnant sheep or sheep used for breeding purposes.

How Supplied: Micotil is supplied in 50 mL, 100 mL and 250 mL multidose amber glass bottles.